pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

151 catalysts · 37 phase 2 completion · 25 phase 1 completion · 21 phase 1 2 completion · 20 phase 2 initiation · 13 phase 1 initiation · 12 phase 1 2 initiation

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-20: 0 catalysts2026-07-21: 0 catalysts2026-07-22: 0 catalysts2026-07-23: 0 catalysts2026-07-24: 1 catalyst2026-07-25: 0 catalysts2026-07-26: 0 catalysts2026-07-27: 2 catalysts2026-07-28: 4 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
TA: multiple-sclerosis×TA: oncology×TA: pain×clear all
type
  • phase 2 completion37
  • phase 1 completion25
  • phase 1 2 completion21
  • phase 2 initiation20
  • phase 1 initiation13
  • phase 1 2 initiation12
  • phase 0 trial completion6
  • phase iv trial initiation3
  • phase 3 completion3
  • phase 3 initiation2
  • therapy area
    • Oncology139
    • Infectious Disease41
    • Cardiology37
    • Immunology32
    • Dermatology27
    • Pulmonology19
    • Women's Health16
    • Ophthalmology15
    • Pain12

    Week of Apr 27, 2026

    50
    ›Apr 29, 2026phase 2 initiation86d agoNational Cancer Institute US — (daratumumab + hyaluronidase (human recombinant)) (Phase II Trial Initiation)(daratumumab + hyaluronidase (human recombinant))

    Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Refractory Multiple Myeloma

    full page →(daratumumab + hyaluronidase (human recombinant)) →source: globaldata
    ›Apr 29, 2026phase 2 initiation86d agoGoa Medical College — diclofenac (Phase II Trial Initiation)diclofenac ER

    Therapy area: Oncology, Toxicology. Indication: Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome), Colon Tumor

    full page →diclofenac ER →source: globaldata
    ›Apr 29, 2026phase 2 results86d agoSt. Vincent Health System — [177Lu]Lu-PSMA-597 (Phase II Trial Results)[177Lu]Lu-PSMA-597

    Therapy area: Oncology. Indication: Hormone-Sensitive Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Prostate Cancer, Prostate Cancer

    full page →[177Lu]Lu-PSMA-597 →source: globaldata
    ›Apr 29, 2026phase 3 completion86d agoAstraZeneca Plc — durvalumab (Phase III Trial Completion)durvalumab

    Therapy area: Genito Urinary System, Oncology. Indication: Bladder Cancer, Bladder Carcinoma, Kidney Cancer (Renal Cell Cancer), Metastatic Transitional (Urothelial) Tract Cancer, Renal Stones/Calculi, Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Ureter Cancer, Urethral Cancer

    full page →durvalumab →source: globaldata
    ›Apr 29, 2026phase 3 initiation86d agoIncyte Corp — retifanlimab (Phase III Trial Initiation)retifanlimab

    Therapy area: Oncology. Indication: Head And Neck Cancer, Head And Neck Squamous Cell Carcinoma (HNSC), Hypopharyngeal Cancer, Laryngeal Cancer, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Recurrent Head And Neck Squamous Cell Carcinoma

    full page →retifanlimab →source: globaldata
    ›Apr 29, 2026phase 3 initiation86d agoInstitute of Hematology and Blood Diseases Hospital — venetoclax (Phase III Trial Initiation)venetoclax

    Therapy area: Oncology. Indication: Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

    full page →venetoclax →source: globaldata
    ›Apr 29, 2026phase iii iv trial initiation86d agoChettinad Hospital and Research Institute — undisclosed local anesthesia (Phase III/IV Trial Initiation)undisclosed local anesthesia

    Therapy area: Central Nervous System. Indication: Pain

    full page →undisclosed local anesthesia →source: globaldata
    ›Apr 29, 2026phase iv trial initiation86d agoNucleic Acids to the Rescue GmbH — undisclosed chemotherapy (Phase IV Trial Initiation)undisclosed chemotherapy

    Therapy area: Oncology. Indication: Small-Cell Lung Cancer

    full page →undisclosed chemotherapy →source: globaldata
    ›Apr 30, 2026fda advisory committee meeting85d agoAstraZeneca Plc — camizestrant (FDA Advisory Committee Meeting)camizestrant

    Therapy area: Oncology. Indication: Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)

    full page →camizestrant →source: globaldata
    ›Apr 30, 2026fda advisory committee meeting85d agoAstraZeneca Plc — capivasertib (FDA Advisory Committee Meeting)capivasertib

    Therapy area: Oncology. Indication: Hormone-Sensitive Prostate Cancer

    full page →capivasertib →source: globaldata
    ›Apr 30, 2026phase 0 trial completion85d agoKunming Yan'an Hospital — dexmedetomidine (Phase 0 Trial Completion)dexmedetomidine

    Therapy area: Central Nervous System. Indication: Pain

    full page →dexmedetomidine →source: globaldata
    ›Apr 30, 2026phase 0 trial completion85d agoRuijin Hospital — dexmedetomidine (Phase 0 Trial Completion)dexmedetomidine

    Therapy area: Central Nervous System, Dermatology. Indication: Burns, Pain, Sedation

    full page →dexmedetomidine →source: globaldata
    ›Apr 30, 2026phase 0 trial completion85d agoSecond Affiliated Hospital of Anhui Medical University — yingtao shujie paste (Phase 0 Trial Completion)yingtao shujie paste

    Therapy area: Oncology, Women's Health. Indication: Breast Cancer, Breast Hyperplasia

    full page →yingtao shujie paste →source: globaldata
    ›Apr 30, 2026phase 0 trial completion85d agoJiangsu Maoxing Technology Co Ltd — MT-026 (Phase 0 Trial Completion)MT-026

    Therapy area: Oncology. Indication: Glioma

    full page →MT-026 →source: globaldata
    ›Apr 30, 2026phase 0 trial completion85d agoFirst Affiliated Hospital of Anhui Medical University — esketamine (Phase 0 Trial Completion)esketamine

    Therapy area: Central Nervous System, Oncology. Indication: Post-Operative Pain, Thyroid Cancer

    full page →esketamine →source: globaldata
    ›Apr 30, 2026phase 0 trial initiation85d agoWashington University School of Medicine — asciminib hydrochloride (Phase 0 Trial Initiation)asciminib hydrochloride

    Therapy area: Oncology. Indication: Brain Tumor

    full page →asciminib hydrochloride →source: globaldata
    ›Apr 30, 2026phase 1 completion85d agoChugai Pharmaceutical Co Ltd — tocilizumab (Phase I Trial Completion)tocilizumab

    Therapy area: Oncology. Indication: B-Cell Non-Hodgkin Lymphoma, Follicular Lymphoma

    full page →tocilizumab →source: globaldata
    ›Apr 30, 2026phase 1 completion85d agoNational Cancer Institute Center for Cancer Research — Anti-CD19/CD20/CD22 CAR T-cells (Phase I Trial Completion)Anti-CD19/CD20/CD22 CAR T-cells

    Therapy area: Oncology. Indication: Acute Lymphoblastic Lymphoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia), B-Cell Leukemia, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Lymphoma, Non-Hodgkin Lymphoma, Unspecified B-Cell Lymphomas

    full page →Anti-CD19/CD20/CD22 CAR T-cells →source: globaldata
    ›Apr 30, 2026phase 1 completion85d agoEOC Pharma Ltd — EOC-237 (Phase I Trial Completion)EOC-237

    Therapy area: Oncology. Indication: Solid Tumor

    full page →EOC-237 →source: globaldata
    ›Apr 30, 2026phase 1 completion85d agoEcolab Inc — (acetaminophen + ibuprofen) (Phase I Trial Completion)(acetaminophen + ibuprofen)

    Therapy area: Central Nervous System, Ear Nose Throat Disorders, Hormonal Disorders, Immunology, Musculoskeletal Disorders, Other Diseases, Women's Health. Indication: Ankylosing Spondylitis (Bekhterev's Disease), Dental Pain (Toothache/Tooth Pain), Fever, Fibromyalgia (Fibromyalgia Syndrome), Gouty Arthritis (Gout), Hyperthyroidism, Laryngitis, Low Back Pain, Mixed Pain (Nociceptive Pain/Neuropathic Pain), Musculoskeletal Inflammation, Musculoskeletal Pain, Myalgia (Muscle Pain), Neuropathic Pa

    full page →(acetaminophen + ibuprofen) →source: globaldata
    ›Apr 30, 2026phase 1 completion85d agoChangzhou Hengbang Pharmaceutical Co Ltd — risvutatug rezetecan (Phase I Trial Completion)risvutatug rezetecan

    Therapy area: Oncology. Indication: Small-Cell Lung Cancer

    full page →risvutatug rezetecan →source: globaldata
    ›Apr 30, 2026phase 1 completion85d agoOncoNano Medicine Inc — cemiplimab (Phase I Trial Completion)cemiplimab

    Therapy area: Oncology. Indication: Basal Cell Carcinoma (Basal Cell Epithelioma), Bladder Cancer, Carcinomas, Cervical Cancer, Cutaneous Squamous Cell Carcinoma (cSCC), Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Head And Neck Squamous Cell Carcinoma (HNSC), Lymphoma, Mantle Cell Lymphoma, Melanoma, Non-Hodgkin Lymphoma, Skin Cancer, Solid Tumor, Triple-Negative Breast Cancer (TNBC), Uveal Melanoma

    full page →cemiplimab →source: globaldata
    ›Apr 30, 2026phase 1 completion85d agoNational Cancer Institute US — tuvusertib (Phase I Trial Completion)tuvusertib

    Therapy area: Oncology. Indication: Adenocarcinoma, Endometrial Cancer, Ovarian Cancer

    full page →tuvusertib →source: globaldata
    ›Apr 30, 2026phase 1 completion85d agoTakeda Pharmaceutical Co Ltd — Cabometyx (Phase I Trial Completion)cabozantinib s-malate

    Therapy area: Oncology. Indication: Solid Tumor

    full page →cabozantinib s-malate →source: globaldata
    ›Apr 30, 2026phase 1 completion85d agoCellenkos Inc — CK-0804 (Phase I Trial Completion)CK-0804

    Therapy area: Oncology. Indication: Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis), Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF)

    full page →CK-0804 →source: globaldata
    ›Apr 30, 2026phase 1 completion85d agoBeOne Medicines AG — BG-89894 (Phase I Trial Completion)BG-89894

    Therapy area: Oncology. Indication: Adenocarcinoma Of The Gastroesophageal Junction, Advanced Malignancy, Bladder Cancer, Esophageal Cancer, Gastric Cancer, Liver Cancer, Malignant Mesothelioma, Non-Small Cell Lung Cancer, Pancreatic Cancer, Solid Tumor

    full page →BG-89894 →source: globaldata
    ›Apr 30, 2026phase 1 completion85d agoAngel Pharmaceuticals Inc — soquelitinib (Phase I Trial Completion)soquelitinib

    Therapy area: Oncology. Indication: Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Cutaneous T-Cell Lymphoma, Natural Killer Cell Lymphomas, Peripheral T-Cell Lymphomas (PTCL), T-Cell Leukemia, T-Cell Lymphomas

    full page →soquelitinib →source: globaldata
    ›Apr 30, 2026phase 1 completion85d agoKyowa Kirin Co Ltd — brentuximab vedotin (Phase I Trial Completion)brentuximab vedotin

    Therapy area: Oncology. Indication: Cutaneous T-Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome

    full page →brentuximab vedotin →source: globaldata
    ›Apr 30, 2026phase 1 completion85d agoShanghai Institute of Biological Products Co Ltd — SIBPA-13 (Phase I Trial Completion)SIBPA-13

    Therapy area: Oncology. Indication: Breast Cancer, Head And Neck Squamous Cell Carcinoma (HNSC), Non-Small Cell Lung Cancer, Solid Tumor

    full page →SIBPA-13 →source: globaldata
    ›Apr 30, 2026phase 1 completion85d agoSun Yat-sen University Hospital Seven — stiripentol (Phase I Trial Completion)stiripentol

    Therapy area: Oncology. Indication: Colorectal Cancer, Gastric Cancer, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cancer

    full page →stiripentol →source: globaldata
    ›Apr 30, 2026phase 1 completion85d agoNational Cancer Institute US — emavusertib hydrochloride (Phase I Trial Completion)emavusertib hydrochloride

    Therapy area: Oncology. Indication: Metastatic Pancreatic Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma

    full page →emavusertib hydrochloride →source: globaldata
    ›Apr 30, 2026phase 1 completion85d agoUniversity of Texas MD Anderson Cancer Center — bevacizumab (Phase I Trial Completion)bevacizumab

    Therapy area: Oncology. Indication: Advanced Malignancy, Metastatic Cancer, Solid Tumor

    full page →bevacizumab →source: globaldata
    ›Apr 30, 2026phase 1 completion85d agoSiteman Cancer Center — soficabtagene geleucel (Phase I Trial Completion)soficabtagene geleucel

    Therapy area: Oncology. Indication: Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Cutaneous T-Cell Lymphoma, Natural Killer Cell Lymphomas, Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphomas (PTCL), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Sezary Syndrome, T-Cell Leukemia, T-Cell Lymphomas, Transformed Mycosis Fungoides

    full page →soficabtagene geleucel →source: globaldata
    ›Apr 30, 2026phase 1 completion85d agoRevolution Medicines Inc — daraxonrasib (Phase I Trial Completion)daraxonrasib

    Therapy area: Oncology. Indication: Colorectal Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Solid Tumor

    full page →daraxonrasib →source: globaldata
    ›Apr 30, 2026phase 1 completion85d agoOno Pharmaceutical Co Ltd — ONO-4578 (Phase I Trial Completion)ONO-4578

    Therapy area: Oncology. Indication: Breast Cancer, Hormone Sensitive Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Metastatic Breast Cancer

    full page →ONO-4578 →source: globaldata
    ›Apr 30, 2026phase 1 completion85d agoDaiichi Sankyo Co Ltd — raludotatug deruxtecan (Phase I Trial Completion)raludotatug deruxtecan

    Therapy area: Oncology. Indication: Kidney Cancer (Renal Cell Cancer), Ovarian Cancer, Renal Cell Carcinoma

    full page →raludotatug deruxtecan →source: globaldata
    ›Apr 30, 2026phase 1 initiation85d agoQilu Pharmaceutical Co Ltd — QLS-5212 (Phase I Trial Initiation)QLS-5212

    Therapy area: Oncology. Indication: Solid Tumor

    full page →QLS-5212 →source: globaldata
    ›Apr 30, 2026phase 1 initiation85d agoVanderbilt-Ingram Cancer Center — nivolumab (Phase I Trial Initiation)nivolumab

    Therapy area: Oncology. Indication: Head And Neck Cancer, Head And Neck Squamous Cell Carcinoma (HNSC), Oral Cavity (Mouth) Cancer, Squamous Cell Carcinoma

    full page →nivolumab →source: globaldata
    ›Apr 30, 2026phase 1 initiation85d agoGan & Lee Pharmaceuticals Co Ltd — GLR-2037 (Phase I Trial Initiation)GLR-2037

    Therapy area: Oncology. Indication: Prostate Cancer

    full page →GLR-2037 →source: globaldata
    ›Apr 30, 2026phase 1 initiation85d agoAvance Clinical Pty Ltd — ZE-740282 (Phase I Trial Initiation)ZE-740282

    Therapy area: Oncology. Indication: Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis), Myeloproliferative Disorders, Polycythemia Vera

    full page →ZE-740282 →source: globaldata
    ›Apr 30, 2026phase 1 initiation85d agoByterna Therapeutics Ltd — BR-101 (Phase I Trial Initiation)BR-101

    Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Refractory Multiple Myeloma, Relapsed Multiple Myeloma

    full page →BR-101 →source: globaldata
    ›Apr 30, 2026phase 1 initiation85d agoBristol-Myers Squibb Co — navlimetostat (Phase I Trial Initiation)navlimetostat

    Therapy area: Oncology. Indication: Biliary Tumor, Bladder Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal (GE) Junction Carcinomas, Malignant Mesothelioma, Malignant Pleural Mesothelioma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Non-Small Cell Lung Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Recurrent Glioblastoma Multiforme (GBM), Solid Tumor, Transitional Cell Carcinoma (Urothelial Cell Carcinoma)

    full page →navlimetostat →source: globaldata
    ›Apr 30, 2026phase 1 initiation85d agoShanghai Henlius Biotech Inc — HLX-3901 (Phase I Trial Initiation)HLX-3901

    Therapy area: Oncology. Indication: Neuroendocrine Carcinoma, Small-Cell Lung Cancer

    full page →HLX-3901 →source: globaldata
    ›Apr 30, 2026phase 1 initiation85d agoCentre Hospitalier Universitaire de Nice — Leucogenase (Phase I Trial Initiation)Leucogenase

    Therapy area: Oncology. Indication: Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

    full page →Leucogenase →source: globaldata
    ›Apr 30, 2026phase 1 initiation85d agoKexing Biopharm Co Ltd — GB-18 (Phase I Trial Initiation)GB-18

    Therapy area: Musculoskeletal Disorders, Oncology. Indication: Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Cachexia, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Solid Tumor, Unspecified Cancer

    full page →GB-18 →source: globaldata
    ›Apr 30, 2026phase 1 initiation85d agoBeOne Medicines AG — BGC-0979 (Phase I Trial Initiation)BGC-0979

    Therapy area: Oncology. Indication: Solid Tumor

    full page →BGC-0979 →source: globaldata
    ›Apr 30, 2026phase 1 2 completion85d agoAbbVie Inc — blinatumomab (Phase I/II Trial Completion)blinatumomab

    Therapy area: Oncology. Indication: Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

    full page →blinatumomab →source: globaldata
    ›Apr 30, 2026phase 1 2 completion85d agoBellicum Pharmaceuticals Inc — acetaminophen (Phase I/II Trial Completion)acetaminophen ER

    Therapy area: Oncology. Indication: Breast Cancer, Lung Cancer, Malignant Mesothelioma, Malignant Pleural Mesothelioma, Metastatic Breast Cancer, Non-Small Cell Lung Cancer

    full page →acetaminophen ER →source: globaldata
    ›Apr 30, 2026phase 1 2 completion85d agoIRCCS Foundation National Cancer Institute — bevacizumab (Phase I/II Trial Completion)bevacizumab

    Therapy area: Oncology. Indication: Metastatic Colorectal Cancer

    full page →bevacizumab →source: globaldata
    ›Apr 30, 2026phase 1 2 completion85d agoZhongshan Hospital — iNKT Cell Immunotherapy (Phase I/II Trial Completion)iNKT Cell Immunotherapy

    Therapy area: Oncology. Indication: Bladder Cancer, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)

    full page →iNKT Cell Immunotherapy →source: globaldata
    ← prev
    page 2 of 4
    next →
    $TAK16.82-0.30%
    $AZN168.27-0.86%
    $INCY116.69+0.78%
    $ABBV256.92+1.43%
    $ECL263.14-1.40%
    $RVMD188.75+3.13%
    $AZN168.27-0.86%
    $ONC326.77+2.14%
    $AZN168.27-0.86%
    $ONC326.77+2.14%